Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Nov 13, 2019- Mr. White will remain Executive Chairman of the Board- Mr. Ford has been elected to the Abbott Board- Nov 6, 2019- Discovery marks the first time a new subtype of HIV-1 has been identified since 2000- Abbott is making this new strain accessible to the research community to evaluate its impact to diagnostic testing, treatments and potential vaccines
-
Oct 22, 2019- One-third of Americans have heard someone say: "I drive better when I've smoked marijuana"- While drunk driving is on the decline, drug-impaired driving is on the rise[1]- Eleven states and Washington, DC, have legalized marijuana for recreational use; Illinois, Michigan are two of the next states to begin adult-use sales in 2020
- Oct 21, 2019Abbott and the Australian Red Cross Blood Service extend 30-year partnership of providing safe, life-saving blood supply in Australia
- Oct 16, 2019- Third-quarter sales growth of 5.5 percent; organic sales growth of 7.6 percent- Exceptional growth across key platforms of FreeStyle Libre, MitraClip and Alinity- Continues to strengthen portfolio with a steady cadence of new product approvals, reimbursement coverage and clinical data
- Oct 15, 2019- Companies aim to integrate Abbott's FreeStyle Libre glucose sensing technology with Tandem's insulin delivery products to expand choices for people with diabetes
-
Oct 15, 2019-- Oct. 17, 2019, marks the one-year anniversary of legalized recreational cannabis nationwide-- A year after legalization, 71% of Canadians are concerned about its impact on road safety-- Survey shows Canadians want more to be done to keep roads safe
Oct 14, 2019- Collaboration combines Abbott′s world-leading glucose sensing technology with Omada Health's best-in-class, proprietary digital coaching platform to provide personalized, on-the-go care- As part of Omada's expanded Type 2 diabetes offering, FreeStyle Libre will be the exclusive CGM delivered directly to participants' doorsteps - expanding access to the technology for more people with diabetes-
Oct 7, 2019- Abbott volunteers work with teachers to empower students to take charge of their health, adopting healthy habits that last a lifetime- Initiative aims to inspire kids to take steps today to prevent chronic diseases tomorrow
- Sep 29, 2019- New late-breaking data at TCT 2019 demonstrate that Abbott's MitraClip™ is cost-effective for heart failure patients with significant secondary mitral regurgitation compared to guideline-directed medical therapy alone- Data analyses presented at TCT demonstrated that over the lifetime of a typical COAPT patient, MitraClip showed improvements in both projected life expectancy and quality of life, and that those benefits are sustained through three years
- Sep 28, 2019- New data presented at TCT 2019 on Abbott's TriClip device from the TRILUMINATE Feasibility Study met both the primary safety and performance endpoints- Abbott's TriClip tricuspid valve repair system design is based on the company's market-leading MitraClip™ technology
- Sep 26, 2019- Proclaim™ XR neurostimulation system uses Abbott's proprietary, low energy BurstDR™ therapy coupled with the BoldXR™ low dosing protocol for safe, effective pain relief and a battery that lasts up to 10 Years*- More than 50 million people in the United States are affected by chronic pain- Abbott's low-dose and low-energy pain management technology is designed to provide pain relief and improve system longevity, offering patients a life-altering option for pain relief without the hassles of recharging
- Sep 25, 2019Newly cleared diagnostic test could help identify heart attacks several hours sooner than standard troponin tests and help improve diagnosis in women
- Sep 17, 2019- World's smallest pediatric treatments pioneered by Abbott address critical needs for the most vulnerable patients: babies and children born with common congenital heart defects- Includes pediatric mechanical heart valve and first minimally invasive device to treat premature babies and newborns born with an opening in their heart
- Sep 16, 2019- Abbott achieves top scores across all three key areas of economic, social and environmental performance, earns more than double the average score in Health Care Equipment & Supplies industry sector- Company's longstanding commitment to sustainability demonstrated by inclusion on DJSI for 15 consecutive years
- Sep 16, 2019- Collaboration aims to provide a connected device experience for millions of people living with diabetes using insulin- Two world leaders in diabetes work together to drive meaningful change in care
- Sep 10, 2019- New research found Abbott's algorithm created through machine learning could give doctors a more individualized calculation, leveraging factors such as age, sex and the changing dynamics of troponin protein levels in the blood, to improve heart attack diagnosis- This technology is the first machine learning developed algorithm that combines high sensitive troponin testing with other patient details to help doctors better determine if a heart attack is occurring
- Sep 9, 2019- New initiative will provide vital primary care services within a 30-minute walk of all Rwandans' homes- Health post workers will test and treat pregnant women for multiple infectious diseases that can have serious health consequences for both mothers and newborns if not diagnosed and treated early
Sep 6, 2019- Beckham will serve as spokesperson and creative director for Pedialyte- Pedialyte provides advanced rehydration, with an optimal balance of electrolytes and glucose- Sep 5, 2019- TRILUMINATE Pivotal trial is the world's first randomized clinical trial to evaluate transcatheter tricuspid valve repair in patients with severe tricuspid regurgitation- There are currently no approved transcatheter tricuspid repair treatments, limiting options for patients with leaky tricuspid valves who are at high risk for surgery- Abbott's TriClip tricuspid valve repair system is built on the company's proven MitraClip technology
- Aug 26, 2019- The TRACK-TBI study found that 64% of people with the highest levels of a protein in the blood were confirmed to have brain injury through an MRI scan, even when a CT scan did not detect it- Abbott's diagnostic test, currently in development, is poised to be the first point-of-care blood test for assessing concussions on its next generation i-STAT™ device, providing doctors results in 15 minutes